drugset / Trial / NCT00787137
Single Dose PG102 in Patients With Active Psoriatic Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how PG102 moves around the body and to explore its effects on the disease.
Timeline
- Start
- 2008-12
- Primary completion
- 2010-04
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PG-102 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | PG-102 | Monoclonal antibody | 1 mg/kg | Intravenous |